Gilead, manufacturer of the TROP2-directed antibody-drug conjugate sacituzumab govitecan, made the decision to withdraw the ...

Cancer vaccines train the immune system to combat foreign invaders like tumours, enhancing the body's ability to recognize ...

If prostate cancer spreads to other parts of the body, it can become deadly and commonly moves to bones, the lungs, lymph ...

The first International Congress on Cancer Genetics is going to be held virtually from October 22 to 24 in Tehran.

Researchers have assembled a single-cell and spatial multi-omics atlas to understand the role of innate immune cells in prenatal skin morphogenesis. Findings were confirmed in a hair-bearing skin ...

Aged just 48, the 11-time Olympic gold medallist tragically has an incurable version of the disease which is expected to hit ...

Pembrolizumab plus chemotherapy improves disease-free survival (DFS) in patients with high-risk endometrial cancer after ...

Gilead is withdrawing the accelerated approval of Trodelvy (sacituzumab govitecan-hziy) for metastatic urothelial cancer.

Recent research from the University of Helsinki sheds new light on the behavior of the KRAS gene in two of the deadliest ...

A decade ago, a person diagnosed with stage four kidney cancer had a survival rate of about a year. Today, advancements in treatment have significantly extended life expectancy more than five years.

Researchers sought to determine whether acalabrutinib plus venetoclax and obinutuzumab based on MRD assessment would yield deep remission in patients with R/R CLL.